These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 8976184)

  • 21. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.
    Stamatatos L; Zolla-Pazner S; Gorny MK; Cheng-Mayer C
    Virology; 1997 Mar; 229(2):360-9. PubMed ID: 9126249
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evidence for non-V3-specific neutralizing antibodies that interfere with gp120/CD4 binding in human immunodeficiency virus 1-infected humans.
    Kang CY; Nara P; Chamat S; Caralli V; Ryskamp T; Haigwood N; Newman R; Köhler H
    Proc Natl Acad Sci U S A; 1991 Jul; 88(14):6171-5. PubMed ID: 2068099
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human antibodies to immunodominant C5 region of HIV-1 gp120 cross-react with HLA class I on activated cells.
    de Santis C; Lopalco L; Robbioni P; Longhi R; Rappocciolo G; Siccardi AG; Beretta A
    AIDS Res Hum Retroviruses; 1994 Feb; 10(2):157-62. PubMed ID: 7515259
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of Broadly Neutralizing Antibodies and Their Mapping by Monomeric gp120 in Human Immunodeficiency Virus Type 1-Infected Humans and Simian-Human Immunodeficiency Virus SHIVSF162P3N-Infected Macaques.
    Jia M; Lu H; Markowitz M; Cheng-Mayer C; Wu X
    J Virol; 2016 Apr; 90(8):4017-4031. PubMed ID: 26842476
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Induced fit in HIV-neutralizing antibody complexes: evidence for alternative conformations of the gp120 V3 loop and the molecular basis for broad neutralization.
    Rosen O; Chill J; Sharon M; Kessler N; Mester B; Zolla-Pazner S; Anglister J
    Biochemistry; 2005 May; 44(19):7250-8. PubMed ID: 15882063
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Induction of cytolytic T lymphocytes directed towards the V3 loop of the human immunodeficiency virus type 1 external glycoprotein gp120 by p55gag/V3 chimeric vaccinia viruses.
    Wagner R; Böltz T; Deml L; Modrow S; Wolf H
    J Gen Virol; 1993 Jul; 74 ( Pt 7)():1261-9. PubMed ID: 7687647
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-human immunodeficiency virus type 1 human monoclonal antibodies that bind discontinuous epitopes in the viral glycoproteins can identify mimotopes from recombinant phage peptide display libraries.
    Boots LJ; McKenna PM; Arnold BA; Keller PM; Gorny MK; Zolla-Pazner S; Robinson JE; Conley AJ
    AIDS Res Hum Retroviruses; 1997 Dec; 13(18):1549-59. PubMed ID: 9430247
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HIV-1 gp120 accelerates Fas-mediated activation-induced human lamina propria T cell apoptosis.
    Boirivant M; Viora M; Giordani L; Luzzati AL; Pronio AM; Montesani C; Pugliese O
    J Clin Immunol; 1998 Jan; 18(1):39-47. PubMed ID: 9475352
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunizations of monkeys with synthetic peptides disclose conserved areas on gp120 of human immunodeficiency virus type 1 associated with cross-neutralizing antibodies and T-cell recognition.
    Vahlne A; Horal P; Eriksson K; Jeansson S; Rymo L; Hedström KG; Czerkinsky C; Holmgren J; Svennerholm B
    Proc Natl Acad Sci U S A; 1991 Dec; 88(23):10744-8. PubMed ID: 1961741
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Protection of neutralization epitopes in the V3 loop of oligomeric human immunodeficiency virus type 1 glycoprotein 120 by N-linked oligosaccharides in the V1 region.
    Losman B; Bolmstedt A; Schønning K; Björndal A ; Westin C; Fenyö EM; Olofsson S
    AIDS Res Hum Retroviruses; 2001 Jul; 17(11):1067-76. PubMed ID: 11485624
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cross-reactive potential of rabbit antibodies raised against a cyclic peptide representing a chimeric V3 loop of HIV-1 gp120 studied by biosensor technique and ELISA.
    Richalet-Sécordel PM; Deslandres A; Plaué S; You B; Barré-Sinoussi F; Van Regenmortel MH
    FEMS Immunol Med Microbiol; 1994 Jun; 9(1):77-87. PubMed ID: 7920467
    [TBL] [Abstract][Full Text] [Related]  

  • 32. V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies.
    Laakso MM; Lee FH; Haggarty B; Agrawal C; Nolan KM; Biscone M; Romano J; Jordan AP; Leslie GJ; Meissner EG; Su L; Hoxie JA; Doms RW
    PLoS Pathog; 2007 Aug; 3(8):e117. PubMed ID: 17722977
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The cross-clade neutralizing activity of a human monoclonal antibody is determined by the GPGR V3 motif of HIV type 1.
    Zolla-Pazner S; Zhong P; Revesz K; Volsky B; Williams C; Nyambi P; Gorny MK
    AIDS Res Hum Retroviruses; 2004 Nov; 20(11):1254-8. PubMed ID: 15588347
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mapping the B cell superantigen binding site for HIV-1 gp120 on a V(H)3 Ig.
    Neshat MN; Goodglick L; Lim K; Braun J
    Int Immunol; 2000 Mar; 12(3):305-12. PubMed ID: 10700465
    [TBL] [Abstract][Full Text] [Related]  

  • 35. V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical Trials Network.
    Montefiori DC; Graham BS; Zhou J; Zhou J; Bucco RA; Schwartz DH; Cavacini LA; Posner MR
    J Clin Invest; 1993 Aug; 92(2):840-7. PubMed ID: 8349820
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate.
    Shibata J; Yoshimura K; Honda A; Koito A; Murakami T; Matsushita S
    J Virol; 2007 Apr; 81(8):3757-68. PubMed ID: 17251298
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhanced activation of human T cell clones specific for virus-like particles expressing the HIV V3 loop in the presence of HIV V3 loop-specific polyclonal antibodies.
    Peifang S; Pira GL; Fenoglio D; Harris S; Costa MG; Venturino V; Dessì V; Layton G; Laman J; Huisman JG
    Clin Exp Immunol; 1994 Sep; 97(3):361-6. PubMed ID: 7915974
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Loss of antibody reactivity directed against the V3 domain of certain human immunodeficiency virus type 1 variants during disease progression.
    Schreiber M; Wachsmuth C; Müller H; Hagen C; Schmitz H; van Lunzen J
    J Gen Virol; 1996 Oct; 77 ( Pt 10)():2403-14. PubMed ID: 8887471
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunochemical analysis of the gp120 surface glycoprotein of human immunodeficiency virus type 1: probing the structure of the C4 and V4 domains and the interaction of the C4 domain with the V3 loop.
    Moore JP; Thali M; Jameson BA; Vignaux F; Lewis GK; Poon SW; Charles M; Fung MS; Sun B; Durda PJ
    J Virol; 1993 Aug; 67(8):4785-96. PubMed ID: 7687303
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of the outer domain of the gp120 glycoprotein from human immunodeficiency virus type 1.
    Yang X; Tomov V; Kurteva S; Wang L; Ren X; Gorny MK; Zolla-Pazner S; Sodroski J
    J Virol; 2004 Dec; 78(23):12975-86. PubMed ID: 15542649
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.